AAML1031: A Phase III Randomized Trial for Patients with de novo AML using Bortezomib (NSC# 681239) and Sorafenib (BAY 43-9006, NSC# 724772) for Patients with High Allelic Ratio FLT2/ITD
Project: Research project
Project Details
Status
Finished
Effective start/end date
4/2/13 → 8/8/13
Funding
Children's Hospital of Philadelphia (COG AAML1031)
Bayer HealthCare Pharmaceuticals, Inc. (COG AAML1031)